Testing CPV-104 safety in healthy people and C3G patients
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called CPV-104. First, healthy volunteers will receive a single dose to check safety. Then, people with C3 glomerulopathy (a rare kidney disease) will receive multiple doses to see if it helps and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For healthy volunteers: age 18-50, good general health, weight between 45-110 kg, and body mass index (BMI) from 18 to 32.
- For C3G patients: confirmed diagnosis by kidney biopsy, protein in urine, and stable kidney disease on current treatment.
- You must not have had any complement-modifying treatment in the last 6 months.
- You cannot have other serious medical conditions or recent infections.
- You must agree to use effective contraception for 90 days after the last dose.
- You cannot donate blood or have donated blood in the past 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well pegcetacoplan works and how safe it is for people with two rare kidney diseases, called C3G and IC-MPGN. It will help doctors understand how the medicine helps patients in real life, outside of a strict clinical trial.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
This Phase 2 study tests KP104 in people with IgA nephropathy (IgAN) or C3 glomerulopathy (C3G) to see if it improves kidney disease and is safe. It also tracks how the body handles the drug and how it affects disease markers in urine and blood.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
This early-phase study tests whether NM8074 can help adults with C3 glomerulopathy. It focuses on people with low blood C3 levels and protein in the urine, and it includes close monitoring and required vaccinations to reduce infection risk.
This early-phase study tests a new inhaled medication called CPD704 in healthy volunteers. It checks safety and how the body processes the drug.
Hear when a new C3 Glomerulopathy (C3G) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.